Drugs / Ranpirnase
Ranpirnase
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02535104 | Feb → Sep 2016 | anogenital human papillomavirus infection | Tamir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01184287 | — | non-small cell lung carcinoma | Tamir Biotechnology, Inc. | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00003034 | May 1997 → Feb 2008 | malignant mesothelioma | Alfacell | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-26 | Okogen | Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio okogen.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ranpirnase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02535104 ↗ |
| Known as | Onconase | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108479 ↗ |
| Known as | P-30 PROTEIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108479 ↗ |
| Known as | Protein p-30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108479 ↗ |
| Known as | Ranpirnasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108479 ↗ |
| Known as | Ribonuclease (rana pipiens) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108479 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108479 ↗ |
| Route | Intravenous | “Given IV” NCT00003034 ↗ |